FDA 510(k) clearance hinges on one concept: substantial equivalence. Medical device manufacturers must prove their device compares favorably to a legally marketed predicate. This article explains the FDA’s criteria, the decision-making process, and the performance data requirements that determine whether your device qualifies for 510(k) clearance.
You’ll learn:
- The three requirements the FDA uses to evaluate substantial equivalence
- How technological characteristics affect your regulatory pathway
- When the FDA requires performance data versus descriptive information
- Common documentation gaps that delay 510(k) review
The Three Requirements the FDA Uses to Evaluate Substantial Equivalence
The FDA cleared 3,882 510(k) submissions in fiscal year 2023. Each required clearance demonstrates substantial equivalence against three mandatory criteria.
| Requirement | What the FDA Evaluates | Common Issues |
|---|---|---|
| Legally Marketed Predicate | The device was marketed before May 28, 1976, reclassified from Class III, or cleared through a prior 510(k) | Citing predicates removed from the market or under judicial action |
| Same Intended Use | General purpose and function match the predicate device | Labeling inconsistencies between indications and proposed use |
| Technological Characteristics | Materials, design, and energy source match or differences don’t raise safety questions | Incomplete specification comparisons |
What Qualifies as a Legally Marketed Predicate
Your predicate must fall into one of three categories: devices marketed before May 28, 1976, devices reclassified from Class III to Class II or I, or devices found substantially equivalent through previous 510(k) submissions.
The predicate cannot have been removed from the market at the FDA’s initiative. The predicate cannot be subject to judicial determination as misbranded or adulterated.
How Intended Use Affects Your Regulatory Decision
Intended use describes the general purpose of your device. This encompasses indications for use, which specify the disease, condition, or patient population your device addresses.
The FDA bases intended use determination on proposed labeling in your 510(k) submission. Different indications may share the same intended use. A fracture fixation plate indicated for diaphyseal fractures and a predicate indicated for epiphyseal fractures share the same intended use: fracture fixation of long bones.
Changes that create new intended use:
| Change Type | Example | Why It Creates New Intended Use |
|---|---|---|
| Anatomical Location | External injury device for use in the internal body cavity | Introduces infection risks not evaluated in the predicate |
| Clinical Context | Periodic monitoring to continuous monitoring | Changes risk exposure duration and failure consequences |
| Patient Population | Adult to pediatric | Alters physiological considerations and dosing requirements |
Technological Characteristics the FDA Examines
Section 513(i)(1)(B) of the FD&C Act defines technological characteristics as materials, design, energy source, and other device features. Your submission must identify these characteristics for both your device and the predicate.
| Characteristic | What to Document |
|---|---|
| Materials | Chemical formulation, additives, coatings, surface modifications |
| Design | Physical specifications, dimensions, tolerances, and component relationships |
| Energy Source | Power delivery, battery specifications, and energy type affect the patient |
| Other Features | Software algorithms, porosity, degradation, assay methods |
Different technological characteristics do not automatically disqualify your device. The FDA evaluates whether differences raise different questions of safety and effectiveness.
How Technological Characteristics Affect Your Regulatory Pathway
The FDA follows a structured decision process. Your answers to five decision points determine whether your device achieves substantial equivalence.
The FDA’s Five-Point Decision Framework
- Decision Point 1: Is the predicate legally marketed? A “no” results in Not Substantially Equivalent.
- Decision Point 2: Same intended use? A “no” results in Not Substantially Equivalent.
- Decision Point 3: Same technological characteristics? A “yes” results in Substantially Equivalent. A “no” proceeds to Point 4.
- Decision Point 4: Do differences raise different safety or effectiveness questions? A “yes” results in Not Substantially Equivalent.
- Decision Point 5: Do data demonstrate equivalence? A “yes” results in Substantially Equivalent.
When Multiple Predicates Support Your Submission
Manufacturers may cite multiple predicate devices when combining features or addressing multiple indications. All predicates must share the same intended use as your device.
A hemodialysis catheter references one predicate for extension design and another for tip design. A multi-parameter patient monitor references different predicates for each measurement technology. The FDA recommends identifying a single primary predicate.
When the FDA Requires Performance Data Versus Descriptive Information
The FDA follows a stepwise analytical process. Each step represents increasing evidence requirements.
The Four-Step Data Request Process
The FDA currently requests clinical data for less than 10% of 510(k) submissions reviewed in the Office of Device Evaluation.
| Step | Evidence Type | Examples |
|---|---|---|
| 1 | Descriptive Information | Materials specifications, dimensional drawings |
| 2 | Non-Clinical Bench Testing | Mechanical testing, EMC evaluation, sterility validation |
| 3 | Animal/Biocompatibility Studies | Tissue response, degradation rates, toxicity assessment |
| 4 | Clinical Performance Data | User performance, clinical outcomes, and real-world effectiveness |
Four Scenarios That Require Clinical Data
- Scenario 1: An over-the-counter blood glucose test system shifts from prescription use. Clinical data demonstrates user competency.
- Scenario 2: A hemodialysis catheter with a different tip design cannot replicate clinical failure modes through bench testing. Clinical data evaluate performance under actual-use conditions.
- Scenario 3: Devices that depend on user interaction or the clinical environment require testing in actual-use settings.
- Scenario 4: New scientific information reveals safety concerns with predicate technology. The FDA requires clinical data for new devices using similar technology.
Non-Clinical Testing the FDA Accepts
Non-clinical laboratory studies supporting safety must comply with 21 CFR Part 58 Good Laboratory Practice regulations.
| Testing Category | Evaluation Focus |
|---|---|
| Mechanical Performance | Fatigue, wear, tensile strength, compression, burst pressure |
| Electrical Performance | Electromagnetic compatibility, electrical safety, and power delivery |
| Biological Performance | Biocompatibility, sterility, and pyrogenicity |
| Software Validation | Algorithm performance, cybersecurity, interoperability |
| Stability/Shelf Life | Degradation, packaging integrity, sterility maintenance |
Common Documentation Gaps That Delay 510(k) Review
The FDA requests additional information when submissions lack completeness. These requests extend review timelines by 180 calendar days.
Insufficient Predicate Documentation
Your submission must contain the predicate 510(k) number, technological specifications, and exact indications for use. FDA records supplement but do not replace manufacturer-provided information.
Incomplete Performance Testing Documentation
Each test must connect to specific device characteristics. Test methodology identifies standards followed. Acceptance criteria establish pass/fail thresholds. Results demonstrate your device meets or exceeds predicate performance.
Missing Standards Compliance Evidence
FDA guidance documents and special controls specify testing requirements for device types. Claims of compliance with standards require supporting data, including biocompatibility evaluations, electrical safety test reports, EMC emissions data, and software validation documentation.
Timeline Expectations for Review
The FDA aims to review Traditional and Abbreviated 510(k) submissions within 90 days. Special 510(k) submissions receive 30-day review periods. Additional information requests extend these timeframes. Manufacturers have 180 calendar days to respond.
Testing Services That Support 510(k) Submissions
MiCOM Labs provides A2LA-accredited testing services (Certificate #2381.01) for 510(k) submissions. The MiTest® platform automates test execution and provides real-time project status. The MiCMS® platform manages certification workflows for regulatory submissions.
Direct Certification Authority in Five Markets
| Market | Regulatory Body | MiCOM Labs Status |
|---|---|---|
| United States | FCC | Telecommunication Certification Body (TCB) |
| Canada | ISED | Foreign Certification Body (FCB) |
| European Union | CE | Notified Body under US-EU MRA |
| United Kingdom | UKCA | Approved Body under US-UK MRA |
| Japan | MIC | Registered Certification Body (RCB) |
Direct certification authority eliminates third-party coordination delays. MiCOM Labs conducts testing and submits applications directly to regulatory authorities.
MiCOM Labs evaluates connected medical devices across wireless technologies, including RF testing up to 220 GHz, EMC/EMI evaluation, electrical safety verification, and environmental testing.
Contact MiCOM Labs to discuss your device specifications, testing requirements, and 510(k) submission timeline. Receive a detailed proposal outlining applicable standards, testing scope, and certification strategy.